Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial

Takenao Koseki   ^{1, 2, 3 *} , PhD ;   Masashi Kondo   ^{4, 5 *} , MD, PhD ;   Hidetsugu Fujigaki   ⁶ , PhD ;   Kayoko Kikuchi   ⁷ , PhD ;   Yuko Oya   ⁴ , MD, PhD ;   Hiroshi Kato   ⁵ , PhD ;   Tomohiro Mizuno   ^{1, 3} , PhD ;   Naotake Tsuboi   ⁸ , MD, PhD ;   Kenji Kawada   ⁹ , MD, PhD ;   Yasuhiro Goto   ⁴ , MD, PhD ;   Naozumi Hashimoto   ⁴ , MD, PhD ;   Kazuyoshi Imaizumi   ⁴ , MD, PhD ;   Akiko Kada   ⁷ , MPH ;   Hikaru Yabuuchi   ¹⁰ , PhD ;   Kuniaki Saito   ^{6, 10} , PhD ;   Hideyuki Saya   ¹¹ , MD, PhD

¹ Department of Pharmacy, Fujita Health University Hospital, Toyoake, Aichi, Japan

² Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan

³ Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

⁴ Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

⁵ Department of Development and Education of Clinical Research, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

⁶ Department of Advanced Diagnostic System Development, Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan

⁷ Center for Translational Research, Fujita Health University, Toyoake, Aichi, Japan

⁸ Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

⁹ Department of Medical Oncology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

¹⁰ Center for Society-Academia Collaboration, Fujita Health University, Toyoake, Aichi, Japan

¹¹ Oncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan

*these authors contributed equally